Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (779)	12/18/2003 4:08:17 PM
From: Icebrg	Read Replies (1) \| Respond to of 2240

Medarex and Cyto Pulse Sciences Announce Research and License Agreement Thursday December 18, 4:02 pm ET PRINCETON, N.J. and HANOVER, Md., Dec. 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) and Cyto Pulse Sciences, Inc., a privately held Maryland corporation, announced today that they have entered into an agreement under which Medarex will have certain exclusive rights to use Cyto Pulse Sciences' proprietary electrofusion technology to derive hybridomas from the Medarex UltiMAb Human Antibody Development System® for the generation of human antibody producing cells. "We believe that Cyto Pulse Sciences' proprietary electrofusion technology can significantly increase the recovery of antibody-producing hybridomas derived from the Medarex UltiMAb(TM) System," said Donald L. Drakeman, President and CEO of Medarex. "The combination of the Cyto Pulse Sciences technology with the Medarex UltiMAb System is another potential advance in the generation of fully human antibody therapeutic drugs through increasing the efficiency of hybridoma production." "This is an important validation of our cell fusion technology for hybridoma production," said Richard E. Walters, President and CEO of Cyto Pulse Sciences.